CTI BioPharma

Vonjo

Pharma

In $1.7B buy, Sobi acquires CTI and myelofibrosis drug Vonjo

Sobi has enhanced its hematology portfolio with a $1.7B acquisition of CTI and its potential blockbuster myelofibrosis treatment Vonjo.

Kevin Dunleavy May 10, 2023 11:25am

Green traffic light

CTI's JAK inhibitor Vonjo finally crossed the FDA finish line

Mar 1, 2022 10:25am